Anika Therapeutics Company Profile (NASDAQ:ANIK)

About Anika Therapeutics

Anika Therapeutics logoAnika Therapeutics, Inc. is an orthopedic medicines company. The Company offers therapeutic pain management solutions. It is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid (HA) technology. It orthopedic medicine portfolio consists of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration. Its therapeutic offerings consist of products in the areas, such as Orthobiologics, Dermal, Surgical, Ophthalmic and Veterinary. It offers products made from HA based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. Its orthobiologics products primarily consist of viscosupplementation and regenerative orthopedics products. Its viscosupplementation franchise includes ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Health Care Supplies
  • Exchange: NASDAQ
  • Symbol: ANIK
  • CUSIP: 03525510
Key Metrics:
  • Previous Close: $44.06
  • 50 Day Moving Average: $46.24
  • 200 Day Moving Average: $48.03
  • 52-Week Range: $34.48 - $54.96
  • Trailing P/E Ratio: 19.23
  • Foreward P/E Ratio: 21.70
  • P/E Growth: 1.42
  • Market Cap: $651.07M
  • Outstanding Shares: 14,777,000
  • Beta: 1.49
  • Net Margins: 33.64%
  • Return on Equity: 17.44%
  • Return on Assets: 15.83%
  • Current Ratio: 14.70%
  • Quick Ratio: 13.06%
Additional Links:
Companies Related to Anika Therapeutics:

Analyst Ratings

Consensus Ratings for Anika Therapeutics (NASDAQ:ANIK) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $49.50 (12.35% upside)

Analysts' Ratings History for Anika Therapeutics (NASDAQ:ANIK)
DateFirmActionRatingPrice TargetDetails
4/27/2016Northland SecuritiesDowngradeOutperform -> Market PerformView Rating Details
2/26/2016Barrington ResearchBoost Price TargetOutperform$45.00 -> $49.00View Rating Details
8/27/2015First AnalysisInitiated CoverageEqual -> Equal WeightView Rating Details
11/12/2014Singular ResearchLower Price TargetBUY -> Buy$51.50 -> $45.50View Rating Details
(Data available from 10/28/2014 forward)


Earnings History for Anika Therapeutics (NASDAQ:ANIK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/26/2016Q316$0.47$0.59$26.60 million$25.79 millionViewListenView Earnings Details
7/27/2016Q216$0.44$0.57$24.75 million$26.60 millionViewListenView Earnings Details
4/27/2016Q116$0.28$0.45$19.26 million$22.30 millionViewListenView Earnings Details
2/24/2016Q415$0.60$0.72$28.19 million$25.60 millionViewListenView Earnings Details
10/28/2015Q315$0.34$0.55$22.36 million$23.70 millionViewListenView Earnings Details
7/29/2015Q215$0.34$0.51$21.65 million$22.90 millionViewListenView Earnings Details
4/28/2015Q115$0.21$0.23$16.20 million$15.50 millionViewListenView Earnings Details
2/25/2015Q414$0.48$0.51$24.60 million$23.30 millionViewListenView Earnings Details
10/30/2014Q314$0.33$0.40$20.33 million$22.10 millionViewListenView Earnings Details
7/30/2014Q214$0.57$0.60$28.20 million$26.27 millionViewListenView Earnings Details
4/29/2014Q114$0.25$0.97$16.03 million$34.00 millionViewN/AView Earnings Details
2/26/2014Q413$0.42$0.44$21.91 million$21.30 millionViewListenView Earnings Details
10/31/2013Q313$0.14$0.33$16.96 million$17.80 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.25$0.40$17.09 million$20.80 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Anika Therapeutics (NASDAQ:ANIK)
Current Year EPS Consensus Estimate: $1.96 EPS
Next Year EPS Consensus Estimate: $2.03 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.19$0.25$0.22
Q2 20162$0.38$0.47$0.43
Q3 20162$0.46$0.47$0.47
Q4 20162$0.47$0.48$0.48
Q1 20171$0.48$0.48$0.48
Q2 20171$0.48$0.48$0.48
(Data provided by Zacks Investment Research)


Dividend History for Anika Therapeutics (NASDAQ:ANIK)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Anika Therapeutics (NASDAQ:ANIK)
Insider Ownership Percentage: 5.80%
Institutional Ownership Percentage: 78.08%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/25/2016Raymond J LandDirectorSell2,695$43.62$117,555.90View SEC Filing  
2/27/2015Raymond J LandDirectorSell4,621$39.49$182,483.29View SEC Filing  
5/1/2014Charles H SherwoodCEOSell83,780$44.32$3,713,129.60View SEC Filing  
2/28/2014Charles H SherwoodCEOSell200,000$41.70$8,340,000.00View SEC Filing  
8/22/2013John C MoranDirectorSell5,000$24.35$121,750.00View SEC Filing  
8/8/2013Steve E WheelerDirectorSell26,984$23.61$637,092.24View SEC Filing  
8/7/2013Steve E WheelerDirectorSell11,016$27.01$297,542.16View SEC Filing  
8/6/2013Farmaceutici S.P.A. FidiaMajor ShareholderSell1,270,000$24.52$31,140,400.00View SEC Filing  
7/15/2013Charles H SherwoodCEOSell75,000$20.11$1,508,250.00View SEC Filing  
7/9/2013Charles H SherwoodCEOSell49,185$18.06$888,281.10View SEC Filing  
7/5/2013Charles H SherwoodCEOSell34,662$18.01$624,262.62View SEC Filing  
6/19/2013Charles H SherwoodCEOSell1,847$18.00$33,246.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Anika Therapeutics (NASDAQ:ANIK)
News IconSEC Filing: Anika Therapeutics INC (ANIK) Share Price Rose While Healthinvest Partners Ab Has Trimmed Its Stake - Chester News (NASDAQ:ANIK) - October 27 at 9:05 PM
News IconHyaluronic Acid Injections Market USD 10.5 Billion by 2020, Research Study Published by iHealthcareAnalyst, Inc. (NASDAQ:ANIK) - October 27 at 3:45 PM logoAnika Therapeutics Inc Earnings Call scheduled for 9:00 am ET today (NASDAQ:ANIK) - October 27 at 3:45 PM logoAnika Therapeutics (ANIK) Tops Q3 EPS by 12c - - (NASDAQ:ANIK) - October 27 at 5:43 AM
News IconAnalysts Taking Aim at Anika Therapeutics Inc. (NASDAQ:ANIK) Ahead of Earnings - CSZ News (NASDAQ:ANIK) - October 27 at 5:43 AM
News IconEarnings Report: EPS Preview for Anika Therapeutics Inc (ANIK) - MoneyMakingArticles (NASDAQ:ANIK) - October 27 at 5:43 AM logoAnika Therapeutics Inc. (NASDAQ:ANIK) Deferred Tax Assets At $0.659 - (NASDAQ:ANIK) - October 27 at 5:43 AM logoAnika Reports Third Quarter 2016 Financial Results (NASDAQ:ANIK) - October 26 at 8:32 PM logoAnika Therapeutics : posts 3Q profit (NASDAQ:ANIK) - October 26 at 8:32 PM logoAnika Therapeutics Inc Earnings Call (Q3 2016) (NASDAQ:ANIK) - October 26 at 8:32 PM logoAnika posts 3Q profit (NASDAQ:ANIK) - October 26 at 8:32 PM
News IconGlobal Hemostats Market New Report by Data Bridge Market Research (NASDAQ:ANIK) - October 26 at 12:27 PM logoQ3 2016 Anika Therapeutics Inc Earnings Release - After Market Close (NASDAQ:ANIK) - October 26 at 12:27 PM logoAnika Therapeutics Inc. (NASDAQ:ANIK) Buy Calls At 0 - Investor Newswire (NASDAQ:ANIK) - October 25 at 8:20 AM
News IconRating Sentiment To Observe: Analysts take a look at Anika ... - MoneyMakingArticles (NASDAQ:ANIK) - October 25 at 8:20 AM
News IconNordea Investment Management AB Reached $2,382,000 position ... - DailyQuint (NASDAQ:ANIK) - October 23 at 8:16 AM logoViscosupplementation Market Detailed Analysis and Forecast by 2026 (NASDAQ:ANIK) - October 21 at 8:33 PM
News IconAnika Therapeutics Inc. (NASDAQ:ANIK) Updated Broker Price Targets - The De Soto Edge (NASDAQ:ANIK) - October 20 at 3:56 PM
News IconKalos Management Inc. Sold shares of Anika Therapeutics Inc ... - DailyQuint (NASDAQ:ANIK) - October 20 at 3:56 PM logoETF’s with exposure to Anika Therapeutics, Inc. : October 20, 2016 (NASDAQ:ANIK) - October 20 at 3:56 PM logoSell Recommendations For Anika Therapeutics Inc. (NASDAQ:ANIK) At 0 - Investor Newswire (NASDAQ:ANIK) - October 18 at 8:18 AM
News IconAnika Therapeutics Inc. (ANIK) Position Decreased by Dimensional Fund Advisors LP - DailyQuint (NASDAQ:ANIK) - October 18 at 8:18 AM
News IconBroker Roundup For Anika Therapeutics Inc. (NASDAQ:ANIK) - The De Soto Edge (NASDAQ:ANIK) - October 16 at 8:17 AM
News IconLatest Analyst Reports On Dimension Therapeutics, Inc (NASDAQ:ANIK) - October 14 at 12:02 PM logoAnika Therapeutics Inc. (NASDAQ:ANIK) Sales Estimate At $119.39 - Investor Newswire (NASDAQ:ANIK) - October 13 at 8:52 PM logoAnika to Issue Third-Quarter 2016 Financial Results and Business Highlights on Wednesday, October 26 (NASDAQ:ANIK) - October 12 at 8:51 PM
News IconAnika Therapeutics Inc. (NASDAQ:ANIK) – Broker Update - NewsDen (NASDAQ:ANIK) - October 12 at 6:22 AM logoDump Horizon Pharma PLC (HZNP) Stock Now! Don't Wait! - (NASDAQ:ANIK) - October 11 at 3:33 PM logoAnika Therapeutics Inc. (NASDAQ:ANIK) Sell Calls At 0 - Investor Newswire (NASDAQ:ANIK) - October 11 at 3:33 PM
News IconFacial Aesthetic Dermal Filler Market: Global Industry Analysis (NASDAQ:ANIK) - October 9 at 3:26 PM
News IconShort Interest Filing: What's Propelling Anika Therapeutics Incorporated (NASDAQ:ANIK) After Lower Shorts Reported? - Post News (NASDAQ:ANIK) - October 7 at 3:30 PM logoAnika Therapeutics Inc. (NASDAQ:ANIK) Projected Sales At $119.39 - Investor Newswire (NASDAQ:ANIK) - October 7 at 8:19 AM logoEli Lilly to Buy Boehringer's Vetmedica Pet Vaccines Unit - Nasdaq (NASDAQ:ANIK) - October 6 at 3:28 PM logoEli Lilly to Buy Boehringer's Vetmedica Pet Vaccines Unit (NASDAQ:ANIK) - October 6 at 9:18 AM logoHyaluronic Acid Products Market - An Analysis of Strategies of Major Competitors (NASDAQ:ANIK) - October 5 at 4:01 PM logoAlkermes Commences Metabolic Study on Schizophrenia Drug - Nasdaq (NASDAQ:ANIK) - October 5 at 8:20 AM
News IconHyaluronic Acid Product Market Analysis, Segments, Growth and Value Chain 2014-2020 (NASDAQ:ANIK) - October 4 at 3:30 PM logoAdhesion Barrier Market in Asia-Pacific is Expected to Grow at 8.8% CAGR During 2016 - 2022: P&S Market Research (NASDAQ:ANIK) - October 4 at 3:30 PM
News IconHorizon Pharma, Express Scripts to Settle Rebate Litigation - Yahoo - Yahoo News (NASDAQ:ANIK) - October 4 at 8:18 AM logoAnika Therapeutics Inc. (NASDAQ:ANIK) Sell Recommendations At 0 - Investor Newswire (NASDAQ:ANIK) - October 4 at 8:18 AM logoHorizon Pharma, Express Scripts to Settle Rebate Litigation - Nasdaq (NASDAQ:ANIK) - October 3 at 3:28 PM logoIntra-Cellular Reports Poor Phase III Schizophrenia Data - Yahoo Finance (NASDAQ:ANIK) - September 30 at 3:57 PM logoExpected For Anika Therapeutics Inc. (NASDAQ:ANIK) Sales Of $119.39 - Investor Newswire (NASDAQ:ANIK) - September 30 at 3:57 PM logoAcelRx (ACRX) Initiates Phase III IAP312 Study on Zalviso - Nasdaq (NASDAQ:ANIK) - September 28 at 3:28 PM logoJazz Pharma Closes Enrollment in OSA Drug Phase III Trial (NASDAQ:ANIK) - September 28 at 3:28 PM logoIonis/Biogen Complete Nusinersen NDA Submission in U.S. - Nasdaq (NASDAQ:ANIK) - September 27 at 3:31 PM logoViscosupplementation Market Revenue to Reach US$ 327.2 Mn by 2026 (NASDAQ:ANIK) - September 27 at 5:26 AM logoCan Shares Of Anika Therapeutics Inc. (NASDAQ:ANIK) Hit $60? - Investor Newswire (NASDAQ:ANIK) - September 26 at 8:29 PM logo13 Health Care Equipment & Supplies Stocks to Buy Now ... - (NASDAQ:ANIK) - September 26 at 3:29 PM logoETF’s with exposure to Anika Therapeutics, Inc. : September 26, 2016 (NASDAQ:ANIK) - September 26 at 3:29 PM


Anika Therapeutics (NASDAQ:ANIK) Chart for Friday, October, 28, 2016

Last Updated on 10/28/2016 by Staff